Invasive lobular breast carcinoma

3 trials 3 recruiting MedDRA PT
3 Registered trials
3 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
SERD 1 substance
Phase II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • GBG Forschungs GmbH Commercial
    CAPIVASERTIB; FULVESTRANT
    2023-509292-17-00 1 country 2024 n=120
    Recruiting

Phase I

2 trials
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-510356-23-00 6 countries 2025 n=76
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2025-521702-18-00 5 countries 2026 n=62
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase I 2
GBG Forschungs GmbH Commercial 1 Phase II 1
New trials by year
2024
1
2025
1
2026
1
← All indication landscapes